Meet Romina Doerig, Developability Expert at CDR-Life. She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic. Her motto: take the chance—you’ll regret the ones you don’t. Fun fact: she never visits the same place twice!

CDR-Life announces CDR609, a novel T-cell engager targeting LGR5—a highly tumor-specific antigen broadly expressed across common solid tumors including colorectal and pancreatic cancer. Built on our M-gager® platform. IND-enabling studies planned for H2 2025. Details: bit.ly/46dO0ne

CEO Christian Leisner talks targeting “clean” cancer antigens with T-cell engagers, early CDR404 data, expansion into autoimmunity (CDR111), Boehringer deal & why Switzerland is ideal for biotech. Full PharmaBoardroom interview: pharmaboardroom.com/interviews/c...

We’re excited to welcome Pascal Touchon to CDR-Life’s Board. With 40 years in biopharma, including roles at Atara, Ipsen & Novartis, Pascal brings strategic insight, deep industry knowledge and a wide global network —perfectly timed as our first T cell engager progresses in Phase 1. bit.ly/4jqKlpf

Chicago bound! The CDR-Life team is heading to #ASCO25 to discuss our M-gager® platform and lead program CDR404, now in Phase 1 for MAGE-A4+ tumors as well as CDR609, our first program targeting a highly cancer specific surface antigen widely expressed in common tumor types. Let’s connect!!

Join CDR-Life at Swiss Biotech Day (May 5–6)! Hear from our VP Clare Price, and meet CEO Christian Leisner, and CBO Sarah Holland, as they showcase how M-gager® is transforming T cell engager therapy. Let’s connect! #SwissBiotechDay #immunotherapy